Wayne State University
Wayne State University Theses

1-1-2014

Effects Of Statin Drugs And Tocotrienol Rich
Fraction Supplementation In Chronic
Hemodialysis Patients And Metabolomic Profile
Eno Latifi
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_theses
Part of the Biochemistry Commons, Chemistry Commons, and the Nutrition Commons
Recommended Citation
Latifi, Eno, "Effects Of Statin Drugs And Tocotrienol Rich Fraction Supplementation In Chronic Hemodialysis Patients And
Metabolomic Profile" (2014). Wayne State University Theses. Paper 306.

This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne
State University Theses by an authorized administrator of DigitalCommons@WayneState.

EFFECTS OF STATIN DRUGS AND TOCOTRIENOL RICH FRACTION
SUPPLEMENTATION IN CHRONIC HEMODIALYSIS PATIENTS AND
METABOLOMIC PROFILE
by
ENO LATIFI
THESIS
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
MASTER OF SCIENCE
2014
MAJOR: NUTRITION AND FOOD SCIENCE
Approved by:

Advisor

Date

© COPYRIGHT BY
ENO LATIFI
2014
All Rights Reserved

DEDICATION

This thesis is dedicated to the significant people in my life:

Benereta and Sulejman Latifi
My beloved parents who never failed to support me through all my trials and tribulation
in life. I would like to thank them for their sacrifices, immigrating to the United State so
my brother and I could have better lives for ourselves. At the same time I would like to
thank them for the life lessons they taught me, financial support and never giving up in
believing in my dreams.

Ivi Latifi
My beloved brother, who is always there for support, believing in my dreams and goals
in life.

Ferit and Sadet Shehu; Shyqeri and Jalldyz Latifi
My grandparents, who inspired me to live a moral life and dedicate my life to helping
others. I thank them for having a hand in raising me.

Besa Zaimi; Akil Shehu; Luljeta Gjevori
My aunts and uncle for supporting, believing in me and always providing life lessons and
advices.

ii

ACKNOWLEDGEMENTS

First and foremost, I owe my deepest gratitude to my supervisor, Dr. Pramod
Khosla, who has guided and supported me from the very beginning. I would like to thank
him for allowing me to join his lab since undergraduate, mentoring me, and supporting my
goals into obtaining a masters by providing the research funds, technical support and his
vast expertise in metabolism. Furthermore I would like to thank my committee members:
Dr. Smiti Gupta, who opened the doors for metabolomics work and who provided the
logistic and technical support for my projects throughout. Dr. Ahmad Heydari who has
provided his expertise in the area of genetics, and support of my project.
I would also like to thank my lab colleagues, especially to Dr. Deepinder Kaur who
was my guide to a Nutrition Food and Science degree, who also opened the doors into
joining the Khosla lab. I would like to give a special thank you, to Dr. Zulfitri ‘Azuan Mat
Daud who has been a great friend, colleague and a great mentor in the area of clinical
research. Another thank you goes to Dr. Arvind Goja for helping in the area of
metabolomics field. Lastly I would like to thank Rami Hanna, Rajeev Shahani, and Aisha
Chudhry for always helping in experiments and being great colleagues by providing a fun
and professional working environment.
A special thank you goes to the health care professionals at Great Lake Dialysis
Clinic which opened their doors for this projected to be conducted and performed at the
highest professional esteem level.

iii

TABLE OF CONTENTS
Dedication .......................................................................................................................... ii
Acknowledgements ........................................................................................................... iii
List of tables’ ......................................................................................................................v
List of figures .................................................................................................................... vi
List of abbreviations and acronyms ................................................................................ viii
Chapter 1: Introduction .......................................................................................................1
Chapter 2: Materials and Methods ....................................................................................18
Chapter 3: Results .............................................................................................................27
Chapter 4: Discussion .......................................................................................................49
Future Directions ..............................................................................................................59
References .........................................................................................................................61
Abstract .............................................................................................................................65
Autobiographical Statement ..............................................................................................68

iv

LIST OF TABLES
Table 1-1: GFR categorical classification .........................................................................10
Table 1-2: Pew effects on ESRD ......................................................................................11
Table 1-3: Vitamin E tocotrienols properties ....................................................................12
Table 3-1: Baseline clinical and demographic characters of the study population ...........33
Table 3-2: Effects of tocotrienol supplementation on plasma lipids in patients also
prescribed statin drugs ......................................................................................................34
Table 3-3: Metabolites of change on ESRD patients using Chenomx identification
analysis when comparing TRF and placebo groups .........................................................35

v

LIST OF FIGURES
Figure 1-1: Treatment modles for CKD pateints with ESRD ...........................................13
Figure 1-2: Biochemical functions ESRD patients experience leading to CVD’s ...........14
Figure 1-3: Vitamin E Tocotrienol and Tocopherol chemical formulas ...........................15
Figure 1-4: Natural dietary sources of Tocotrienols .........................................................16
Figure 1-5: Tocotrienol antioxidant/anti-inflammatory properties, effect in biomarkers .17
Figure 3-1: Depicts TRF study selection of patients’ flow chart ......................................36
Figure 3-2: Comparison of CETP levels over time in TRF and Placebo groups ..............37
Figure 3-3: CRP comparison between TRF groups and placebo groups ...........................38
Figure 3-4: NFκB activity between TRF and placebo groups ..........................................39
Figure 3-5: Change in TAG levels among statin and non-statin groups ...........................40
Figure 3-6: Change in time of HDLC-C levels among statin and Non-statin Groups ......41
Figure 3-7: PCA score plot in plasma samples from ESRD patients at baseline .............42
Figure 3-8: PCA score plot in plasma samples from ESRD patients at Week 12 ............43
Figure 3-9: PLS-DA score plot in plasma samples from ESRD patients at Week 12 ......44
Figure 3-10: PLS score plot correlating metabolomic profiles and plasma lipids profiles
(TC, TAG, and HDL-C) at week 12 .................................................................................45

vi

Figure 3-11: PLS score plot correlating plasma metabolite profiles to CRP and IL-6
levels .................................................................................................................................46
Figure 3-12: PLS score plot, correlation of metabolomic profiles in the plasma to the
serum albumin levels at week 12 ......................................................................................47
Figure 3-13. PLS correlation of TAP and MDA compared to metabolomic profiles in the
plasma week 12 .................................................................................................................48

vii

LIST OF ABBREVIATIONS AND ACRONYMS
AA

:

Amino Acids

ApoA1

:

Apo-Lipoprotein A1

B.P.

Blood Pressure

BMI

:

Body Mass Index

CETP

:

Cholesteryl Ester Transfer Protein

CKD

:

Chronic Kidney Diseases

CRP

:

C - Reactive Protein

CVD

:

Cardiovascular Disease

eGFR

:

Estimated GFR

ESRD

:

End Stage Renal Disease

GFR

:

Glomerular Filtration Rate

Hb

:

Hemoglobin

HD

:

Hemodialysis

HDL-C

:

High Density Lipoprotein Cholesterol

IDL

:

Intermediate Density Lipoprotein

IL-6

:

Interleukin-6

viii

IQR

:

Interquartile Ranges

KDIGO

:

Kidney Disease Improving Global Outcomes

KDOQI

:

Kidney Disease Outcomes Quality Initiative

Kt/V

:

Dialyzer Clearance x Time Over Volume Distribution of Urea

LDL-C

:

Low Density Lipoprotein Cholesterol

MDA

:

Malondialdehyde

MVDA

:

Multivariate Data Analysis

NFκB

:

Nuclear Factor Kappa B

NMR

:

Nuclear Magnetic Resonance

PCA

:

Principal Component Analysis

PEW

:

Protein Energy Wasting

PLS

:

Partial Least Square

PLS-DA

:

Partial Least Square – Discriminant Analysis

RCT

:

Randomized Controlled Trial

RRT

:

Renal Replacement Therapy

SCr

:

Serum Creatinine

SD

:

Standard Deviation

ix

SEM

:

Standard Error of Mean

Ser. Alb

:

Serum Albumin

SR-B1

:

Scavenger Receptor Class B-1

SREBPs

:

Sterol Regulatory Element Binding Protein

TAG

:

Triacylglycerol

TAP

:

Total Antioxidant Power

TC

:

Total Cholesterol

TNF- α

:

Tumor Necrosis Factor Alpha

TP

:

Tocopherol (Vitamin E)

TRF

:

Tocotrienol-Rich Fractions (Vitamin E)

TT

:

Tocotrienol

USRDS

:

US Renal Data System

VLDL

:

Very Low Density Lipoprotein

WHO

:

World Health Organization

x

1
CHAPTER 1
INTRODUCTION
Chronic Kidney Disease and End-Stage Renal Disease
Chronic kidney disease (CKD) is a heterogeneous disorder which currently is on
the rise and has been classified as a serious public health issues in the United States and
worldwide. The disease effects both kidneys, and is defined as a progressive decline in
kidney structure and functions. If present for more than three months, it has serious
implications for patient health [1]. In the United States the disease effects more than 10%
of adults (more than 20 million people). Based on a National Health and Nutrition
Examination Survey (NHANES) between 1988-2008 the prevalence of CKD has grown
most rapidly in people of ages 60-70 years and older jumping from 18.8 to 26.0 percent
(NKUDIC) [2, 3]. In simplistic terms, this condition is one in which the kidneys are
damaged to a point where the organs cannot filter blood to maintain adequate living for the
patient. Individuals who are considered to be at risk for CKD, are generally adults with
diabetes or high blood pressure, or both. Approximately 1 of 3 adults who have diabetes
and 1 of 5 adults with high blood pressure have some form of CKD in the United States
according to CDC investigation [4]. Other noticeable risk factors for CKD include
cardiovascular disease, obesity, high cholesterol, lupus, and family history of CKD. The
risk of developing CKD further increases with age; while CKD is more common among
women, it is estimated that men with CKD are 50% more likely than women to progress
into kidney failure [4].
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Testing for Kidney Disease
The damage due to various kidney diseases can be asserted medically by looking
at patient’s glomerular filtration rates (GFR). A GFR below 60 mL per min for more than
3 months or when patient’s urine albumin-to-creatinine ratio is over 30mg/g, classifies
these individuals to be suffering from CKD [1, 2] refer to Table 1-1. Newer methods to
calculate renal functions, also use estimated GRF (eGFR), in which case only a
measurement of creatinine levels in the blood is needed. An eGFR of 90 or above is
considered to be normal. Dialysis or kidney transplant is required at an eGFR of <
15mL/min Table 1-1.
Treatment Methods
CKD patients with ESRD have three treatment options; 1) hemodialysis, 2)
peritoneal dialysis or 3) a kidney transplant. Hemodialysis (HD) utilizes a man-made
membrane (dialyzer or hemodialyzer) in order to remove waste products from the blood
(e.g. urea), it restores proper balance of electrolytes in the blood and eliminates extra fluids
from the body. This treatment usually occurs in the presence of health care professionals
in the hospital or clinics usually done 3 days (or every other day) a week and 3-5 hours a
day [5]. Certified dialysis practitioners create a fistula connected to one of the arteries,
which connects to the veins in the lower arm in order to obtain access to the blood
circulatory system so dialysis can proceed [5]. Peritoneal dialysis uses a membrane inside
the patient’s body (peritoneal membrane) as the filter to clean wastes and extra fluid from
the body and returns the electrolyte level to normal. This is a process that does not requires
in-center treatment like hemodialysis does, and can be performed at a home setting so long
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as a catheter is placed into the bell [6]. The last treatment for CKD patients is to obtain a
new kidney via a transplant. It is a procedure which requires surgery and a donated kidney,
other from a living related relative, unrelated donor (friends) or a deceased donor. The
various options are shown in Figure 1-1.
CKD and ESRD
End-stage renal disease (ESRD) occurs when the (eGRF <15 mL/min/ 1.73 m2)
(Stage 5 of CKD), when both organs are in a total or permanent failure. When the kidneys
do fail, the body retains fluids and harmful wastes build up. Once diagnosed with ESRDS,
CKD patients need renal replacement therapy (RRT) to replace the work performed by the
failing kidneys in order to sustain life [2]. Currently the most common RRT in the US is
hemodialysis (HD) which accounts for 98% of the total cases of patients with ESRD [1].
In the USA incidents of ESRD increased steadily from 1980-2001 but they seem to be
leveling off by approximately 350 per million population (pmp) [7]. It was estimated that
in 2011, roughly 113,136 patients in the USA began treatments for ESRD, and of those
patients 7 of 10 new cases, had prior involvement or complication with diabetes and
hypertension. Diabetes mellitus (DM) and hypertension are two of the leading causes of
ESRD. Other disease which lead to ESRD includes, autoimmune disease (lupus
erythematous associated nephritis), drug toxicity, glomerular disease (caused by hepatitis
B, C, and HIV viruses) and tubular interstitial nephritis [7].
Comorbid Conditions
Chronic kidney Disease (CKD) patients with ESRD are known to have systemic
oxidative stress which puts them at high risks for the development of cardiovascular disease
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(CVD), which is currently the leading cause of morbidity and mortality in this population
[8]. ESRD patients, on chronic HD also experience an accelerated form of atherosclerosis,
which is induced by inflammation, impairment of antioxidant system and elevated
oxidative stress. Patients’ who incur ESRD; show evidence of increasing risks of
hospitalization, complications from cardiovascular disease, malnutrition, and chronic
inflammation [9, 10]. The alarmingly increase, in rates of cardiovascular complications
like cardiovascular disease (CVD) currently accounts for 50% mortality rates in ESRD
patients which are estimated to have a 15 to 30 times higher chance than the general agematched population to experience a cardiac event [9, 11]. One of the most common forms
of CVD that ESRD patients experience include acute myocardial infractions, and different
forms of atherosclerotic vascular dieses (e.g. stroke, chronic coronary artery disease and
transient ischemic attacks) [11]. Atherosclerosis is an inflammatory process initiated by
many factors including accumulation of low-density lipoprotein (LDL) in the arterial walls
Figure 1-2. Elevated plasma LDL after exceeding a certain threshold (high LDL levels),
enters the arteries at a fast pace, at which point removal occurs at slower rate, and this leads
to accumulation. This LDL is one of the contributors to atherosclerosis [12, 13].
Comorbidities to ESRD, can involves organs other than the kidneys which may also
be responsible for renal failure (e.g. diabetes mellitus, myeloma) [14]. In ESRD patients
comorbidities include inflammation, oxidative stress and protein-energy wasting (PEW)
[15]. Oxidative stress is referred to as a situation in which pro-oxidants overwhelm
antioxidant defenses, resulting in increased biomarkers of oxidative damage and the
accumulation of free radicals such as reactive oxygen species (ROS) and nitrogen species
(RNS) [16]. In retrospect oxidative stress is linked to CVD because it is involved in the
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modification of LDL, which instigates a cascade of reactions including adhesion of
circulating monocytes on endothelial cells, monocytes migrating into arterial intimal,
platelets activation and expression of various tissue factors by endothelial cells [17]. A
highly prevalent comorbid condition that effects ESRD population is PEW which is known
to be a very strong predictor for adverse outcome and mortality. PEW is characterized by
the loss of muscle mass, weight loss (unintentional), a significant decline in nutritional
parameters such as albumin, pre-albumin [18, 19] derangements of adipose tissues, and
gastrointestinal, hematopoietic and immune systems issues due to deficiencies of multiple
micronutrients. Other effectors which add to the increase in mortality rates of CKD patients
with ESRD due to PEW are hypoalbuminemia, low serum cholesterol levels, low body
mass index a reduced dietary protein intake [19]. The low serum albumin that is present in
the ESRD population due to inadequate energy and protein intake, leads to loss of amino
acids during dialysis and to non-compliance to fluid restriction. Albumin contains thiol
moieties, an important antioxidant in plasma, so low plasma albumin correlates with low
plasma total antioxidant capacity which than links with cardiovascular mortality in ESRD
patients with hypoalbuminemia [20]. PEW furthermore is linked to persistent malnutrition
and inflammation, which is responsible for a cascade of reaction that ultimately causes an
increase in resting energy expenditure, loss of muscle mass and oxidation [21] Table 1-2.
Thus dietary intervention maybe potentially beneficial for CKD patients with
ESRD in order to improve comorbid conditions, like inflammation, oxidative stress, PEW
which seems to be effectors that accelerate CVD’s and increase mortality. So far a limited
number of dietary intervention studies in ESRD patients have focused on
foods/supplements with anti-inflammatory and antioxidant effects as a means to decreasing
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the various comorbidities. The study “Secondary Prevention with Antioxidants of
Cardiovascular Disease in End State Renal Disease (SPACE),” demonstrated that
supplementation with 800 IU of vitamin E per day decreased the overall mortality and
morbidity based on composite cardiovascular end points [22]. Other studies involving
omega-3 fatty acids in HD population have demonstrated that these nutrients possess
beneficial anti-inflammatory, antioxidant and lipid altering properties in-vivo, in-vitro and
clinical settings [23-25].
Potential Nutritional Agents to Reduce Comorbid Conditions:
Vitamin E Tocotrienol
Vitamin E encompasses different isomers. They are composed of two categories tocopherols and tocotrienols. The four saturated analogues alpha (α-), beta (β-), gamma (γ) and delta (δ-) are known as tocopherols (TP) which consist of a chromanol ring 15-carbon
(phytyl) tail. The other forms of vitamin E are the four unsaturated (α-, β-, γ-, and δ-)
analogues referred to as tocotrienols (TT) which possess a chromanol ring with three transdouble bonds toward the end of their farnesyl isoprenoid tail, distinguishing TT from TP
[26, 27] Figure 1-3. Biological half-life of TT is considerably shorter than TP (by 4.5 to
8.7 fold). Vitamin E tocotrienols are compounds which are lipid rich plant products, natural
and found in select vegetable oils. A good source for TT can be found in cereal grains
exemplified by oat, barley and rye, while natural sources of TT are found in annatto, palm
oil, and rice bran oil [27] Figure 1-4.
The structural differences of TT, three unsaturated bonds on the side chain may
accounts for why tocopherols do not have the cholesterol-lowering properties which are in
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TT. This is due to the fact that tocotrienols down-regulate 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-COA) reductase activity which happens to be the rate limiting activity
in the mevalonate pathway that contributes to the synthesis of cholesterol [27]. TT have
also exhibit cardio protective effects including raising serum HDL-C, and inhibiting
oxidation of LDL, plaque instability, thrombogenesis, platelet aggregation, monocyte
adhesion and various other cardiovascular dysfunction [27]. The absorption mechanism for
all 8 isomers vitamin E is described to be similar as the lipid molecules, which means
vitamin E is incorporated into mixed micelles and up taken by enterocytes. This uptake of
vitamin E and mixed micelles are hypothesized to occur via simple passive diffusion as
well as through intestinal scavenger receptor class B type I (SR-B1) [28]. Unfortunately
the cellular mechanism for intracellular trafficking of vitamin E to be elucidated [28].
Chemically vitamin E functions as an antioxidant. Both tocopherols and
tocotrienols have antioxidant activity due to their ability to donate a hydrogen atom (proton
plus electron) from the hydroxyl groups on the chromanol ring, to a free radical in the body.
However lately TT have also gained increasing attention due to indication of them
possessing additional therapeutic properties [26]. Some potential therapeutically effects of
TT are summarized in Table 1-3. A recent study on type 2 diabetic rats with (TRF) showed
the activity of antioxidant enzymes (i.e. superoxide dismutase, and glutathione peroxidase)
was restored and malondialdehyde (MDA), an oxidative stress marker, were reduced when
compared to the untreated groups [29]. Effects of tocotrienol are also seen in the antiinflammatory arena, where there are several lines of evidence that TT could block
activation of NFκB, a family of transcription factors which play central role in regulation
of genes critical for inflammation and immunity[30]. TRF is also described to obtain the
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ability to effect in reducing IL-6, cytokines activity and inhibits LPS-induced secretion of
TNF, further up/down regulation TT targets can be observed by Figure 1-5 [26].
Statin Drugs Effects
This clinical intervention with TRF supplementation unlike other studies uses
humans for subjects, of which are faced by the daily scrutiny of living with renal disease.
Because of the multi-factorial affects that HD patients are face by, few subjects in this
study were allowed to continue with their use of the statins medication (previously
prescribed by their physician) in addition to TRF supplementation Figure 3-1. In general
when statin drugs are used by these patients, metabolic pathways are affected. In specifics
the drugs effect HMG-CoA reductase, were inhibitors (e.g. statin) use has been associated
with reduced mortality from CVD’s in patients with ESRD [31]. Studies have shown that
when combining gamma-tocotrienols and statin drugs together on human malignant
mesothelioma cells, a synergistic effect has been observed to associate and affect the
outcome of the treatment for better. This combination effects was confirmed to be mediated
by the inhibition of the mevalonate pathway, and effect were shown from apoptosis against
malignant mesothelioma cell [32].
Rationale of the Study
Even though much knowledge has been obtained throughout the years in
understanding the complex pathophysiology on what causes CVD complications in CKD
patients with ESRD, unfortunately multifaceted clinical intervention aimed at improving
CVD outcome in HD patients have been unsuccessful in solving the complete puzzle. This
is evident from the fact that around two thirds of dialysis patients die within five year of
having dialysis procedure encore, even though technology, medical techniques, and drugs
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have improved drastically [33]. When it comes to mortality rates in ESRD patients in the
United States, it is estimated to be as high as > 20% per year which is worse than cancer
deaths [34].
Since the problems effecting ESRD patients are multifactorial issues, the objective
of this study is to investigate the effects of supplementing with vitamin E-tocotrienol rich
fraction (TRF), a micronutrient which has anti-inflammatory, antioxidant, and lipid lower
capabilities into tackling these comorbid conditions experienced by this population.
Therefore the aims of this investigation will be to explore changes in lipid profiles,
inflammatory markers, and oxidative status as well as look into any changes in ESRD
metabolomic profiles. Because of previous studies on human malignant mesothelioma
cells, will explore if there are any synergistic effects found by supplementing TRF and
statin drugs together when analyzing lipids and metabolite profiles in ESRD patients.
Hypothesis
It is hypothesized that by supplementing with tocotrienol rich fraction (TRF)
vitamin E, for 16 weeks in ESRD patients undergoing hemodialysis it may help reverse
and/or improve, oxidative status, inflammatory markers, increase antioxidants status and
improve lipid profiles.

10
Table 1-1. GFR Categorical Classification

CKD- Chronic Kidney Disease; GFR- Glomerular Filtration Rate.
Current CKD staging based on GFR kidney function as is described by the guidelines of
KDIGO 2013. In the absence of evidence kidney damage, neither GFR category G1 nor
G2 fulfill the criteria for CKD [1].
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Table 1-2. PEW effects on ESRD

CKD- Chronic Kidney Disease; ESRD- End-Stage Renal Disease.
A list of potential causes of protein energy wasting (PEW) on CKD patients’ with ESRD
population [21].
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Table 1-3. Vitamin E tocotrienols properties

(Sources: Frank et al., 2012; Prasad 2011; Vasanthi et al 2012)
TT- tocotrienol; TP- tocopherols; CRP- C-reactive protein; IL- interleukin; TNF- α- tumor
necrosis factor alpha; VCAM-1- vascular cell adhesion molecule 1; ICAM-1- intercellular
adhesion molecule 1; NFκB- nuclear factor kappa B; HDLC- high density lipoprotein
cholesterol.
This show the potential mechanism of tocotrienols in reducing risk for CVD’s. This depicts
the contributing points, of antioxidant, anti-inflammatory, lipid altering, suppression of
atherosclerosis and anti-thrombogenesis.
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Figure 1-1. Treatment modles for CKD pateints with ESRD.

B

A

C

Figure A) Hemodialysis;

B) Peritoneal Dialysis; C) Kidney Transplant.

A) Hemodialysis model the patients blood is pumped out of the body and passed through
a dialyser membrane which allowes for diffusion of fluids and other waste substances
across the semipermeable membreane (most common treatment in USA). B) Peritoneal
dialysis uses the patients own peritoneum membrane to filter out fluids and other dissolved
substances. C) A kidney from a donor is transplated in the iliac fossa, in the recipients
contra lateral side. (Source: NKUDIC, 2013)
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Figure 1-2. Biochemical functions ESRD patients experience leading to CVD’s

Th- T-helper cell; CRP- C-reactive protein; VCAM- vascular cell adhesion molecules;
ROS- reactive oxygen species; MMPs- matrix metalloproteinase; AngII- angiotensin II;
ox-LDL- oxidized low-density lipoprotein
A) Depicts the biochemical, functional and anatomic evaluation of coronary heart disease
in ESRD patients. B) Show the atheroma’s development processes. Depicts the normal 3
layers of cell arteries who progress into early atheroma. Early artherogenesis, fatty streak
is developed as a result of recruitment of inflammatory cells and foam cells (from
accumulated lipids). When dyslipidemia and inflammatory conditions persist, lipid pool
increases. Activated leukocytes secrete proteinase which caused degradation of the
extracellular matrix and ultimately cell death. Th1 is stimulated by the presence of
inflammatory cytokines that limits the synthesis of new collegen and may thin fibrous cap
which may lead to rapture. Th2 activity leads to a more stable plaque and less susceptibility
to rupture. C) Depicts certain therapeutic measures to be implemented according to
different evolution phases of the atherosclerotic lesion [13]. (Source: Stenvinkel et al 2003)
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Figure 1-3. Vitamin E Tocotrienol and Tocopherol chemical formulas

TT

TP

(Source: Aggarwal et al 2010)
Depicts the eight (8) known forms of vitamin E – isomers, in order α-, β-, δ-, γ- tocotrienols
(TT) vs. tocopherols (TP) differ based on the number of methyl group and chromanol ring
(15-carbon tail). TP are also different from TT due to the present of saturated chain rather
than unsaturated chain. TT which possess an isoprenoid side chain and have the presence
of three trans-double bond in the tail distinguish it against TP [26].
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Figure 1-4. Natural dietary source of Tocotrienols

Barley
Palm oil
Rice bran
Oat
Wheat germ
Coconut oil

α
β
γ
δ

Palm kernel
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Safflower oil
Soy bean oil
Olive oil
0

200

400

600

800

1000

µg/g
(Source: Aggarwal et al. 2003)

The figure shows the natural dietary sources of tocotrienol (TT), expressed in μg per gram.
TT is abundant in palm oil, rice bran, barley, oat and wheat germ, while minimal contained
in peanut oil, safflower, soybean, cocoa butter and olive oil [26].
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Figure 1-5. Tocotrienol antioxidant/anti-inflammatory properties, effect in biomarkers

Down-regulated

Up-regulated

(Source: Aggarwal et al. 2003)

Figure depicts the molecular targets of Tocotrienols as an anti-inflammatory.
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CHAPTER 2
MATERIALS AND METHODS
Study Design
The general aim of the study was to investigate the effects of supplementing vitamin
E- tocotrienols on hemodialysis population, and after analyze any changes induced by this
lipid altering, antioxidant, and anti-inflammatory agent, on the patients’ metabolites
profile. The study was double-blinded, randomized, parallel, placebo-controlled design
trial, of 81 adult’s patients undergoing chronic hemodialysis at Great Lake Dialysis Clinic,
Detroit MI, where patients routinely received hemodialysis treatments 3 days a week. The
protocol for this clinical trial was approved by the Human Investigation Committee of
Great Lake Dialysis Clinic, (case: IRB #00007308) and Wayne State University (case: IRB
#067411A).
Subject Selection
For this clinical trial intervention there were initially screened 118 patients. From
this batch of patients, 37 were excluded due to the fact they did not meet the inclusion
criteria (n=30), and (n=7) patients declined to participate. Thereafter 81 of these
hemodialysis patients were randomly divided into two different groups before the
intervention began; a placebo group (n=37) and intervention group TRF (n=40) Figure 31. The final number of participants were randomized into blocks in order to keep the size
of treatment groups similar, and block size randomization selection was utilized in order
to reduce any bias (Saghei 2004). In metabolomics analysis patients pool selected was
(n=15) ESRD patients, of which (n=7) samples came from placebo group and (n=8) came
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from TRF group. For this metabolomic analysis patients which utilized statin medication
were excluded and only baseline and week 12 plasma samples were tested.
Nutritional Intervention
In order to provide a controlled environment to administer the supplement, gel
capsules were given to both groups’ placebo and TRF; on dialysis and non-dialysis days.
During dialysis day capsules were oral consumed by the patients at the clinic where they
were monitored by researchers in order to observe patients compliance in taking the
capsules. For non-dialysis days capsules were provided for subjects to consume at home.
The placebo group supplement contents, consisted of wheat germ oil with a mixture
of 0.24 mg of tocotrienols and 0.44 mg of tocopherols per capsule. The intervention group
received tocotrienol-rich fraction (TRF) capsule consisted of palm fruit oil, containing a
mixture of 90 mg of tocotrienols and 20 mg of tocopherols, for a total 110 mg of vitamin
E per capsule. A summary of the TRF and placebo capsules composition that the
participants were provided with, for consumption is as follows; both TRF and placebo
capsules, the oil mixtures were composed of Tocopherol (TP) and Tocotrienol (TT) vitamin
E which was measured in (mg). Each TRF capsule was composed of (20.0 mg) of α-TP
and no (β, γ, δ)-TP into the mixture, than other main ingredient were comprised of (30.18
mg) of α-TT, (5.30 mg) of β-TT, (41.66 mg) of δ-TT, (12.86 mg) of γ-TT for an overall 90
mg of TT from palm fruit oil. The composition of placebo capsule was made of (0.29 mg)
of α-TP, (0.04 mg) of β-TP, no- δ-TP, (0.11 mg) of γ-TP, and into the mixture (0.12 mg)
of α-TT, (0.06 mg) of β-TT, no- δ-TT, (0.06 mg) of γ-TT, for an overall 0.68 mg. Therefore
the placebo control group capsule had 0.24 mg of TT and 0.44 mg of TP derived from
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wheat germ oil. The established daily dose supplemented orally for patients was: 2 x 110
mg/day as provided by (Carotino, Johor Darul Takzim, Malaysia) for a total of 220 mg/day,
for 16 weeks [35].
Blood Samples Collection and Handling
Blood samples were collected from the patients at the start of the dialysis session
into vacutainer tubes containing EDTA or heparin and transported to Wayne State
University within 2 hours of collection. Additional blood was collected into separate tubes
without anticoagulant for standard renal profiles measurements which were sent to an
external laboratory (Ser., Alb, Hb, Kt/V) (Ascend Clinical Laboratory Services, Redwood
City, CA, USA). The tubes which contained EDTA were designed for the analyses of lipid
profiles and NFKB, whereas lithium heparin tubes were for the analysis of oxidative status
and inflammatory markers. The plasma processing and separation was conducted by
centrifugation at 2800 rpm for 20 minutes at 4°C (GS-6KR Centrifuge, Beckman-Coulter).
The aliquots of plasma were then stored at -80°C. In the case of the blood samples which were
used to analyze nuclear factor kappa B (NFKB) were processed immediately in order to obtain

mononuclear cell extract using Ficoll-Paque method.
Anthropometry Measurements
Anthropometric measurements were carried out by estimating dry weight and
height at the baseline and the end of the study. The height was measured to the nearest 0.1
cm using whereas the body weight was measured at the nearest 0.1 kg, after each dialysis
session. BMI was calculated from the measurements of weights over height using
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Quetelet’s Index [36] and the data was compared with WHO classification database charts
[37].
Biochemistry Assay, (Lipids Profiles)
For biochemical analysis this clinical study focused on measuring renal profiles, lipid
profiles, and inflammatory markers.
1) Renal profile was determined based on standard measures: Serum albumin (ser. Alb.),
hemoglobin (Hb), and (Kt/V). This analysis was performed by external laboratories.
2) Lipid profiles: Total cholesterol (TC), triacylglycerol (TAG), high density lipoprotein
cholesterol (HDL-C), and Cholesteryl ester transfer protein (CETP) analysis were
conducted using enzymatic assays.
3) For inflammatory markers, the conducted measurements were: C-reactive protein
(CRP) and nuclear factor kappa B (NFκB).
Lipid Profiles
For lipoprotein profile, the study measured TC and TAG levels using commercially
available enzymatic kits (Pointe Scientific, Canton, MI) and values were expressed as
mg/dL for all samples [35].
Measurements for HDL-C were conducted in the supernatant fraction following
precipitation of ApoB contacting lipoprotein from. LDL-C was calculated using the
Friedewald’s equation by difference [35, 38]. CETP activity in the plasma was measured
using fluorometric assay kit. In this case the intensity was measured using a fluorometer at
465nm wavelength quantified and expressed as pmoles/ μL plasma/hour [35] per protocol.
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Inflammatory Markers
To measure C-reactive protein (CRP) activity commercial kits were used (Cayman
Chemical, Ann Arbor, MI). In this case the plasma samples were diluted in the assay
1:15,000 and 100 μL of each sample placed into 96-wells micro-plate pre-coated with a
monoclonal antibody specific to human CRP and then incubated. The well-plates were
rinse 4 times with wash buffer before adding HRP-labeled CRP monoclonal antibody. Two
antibody were added to form a sandwich by binding to different location in the CRP
molecule samples. Lastly CRP concentration in the plasma samples were measured at
450nm wavelength after adding chromogenic substrate TMB (tetramethylbenzidine) which
formed a yellow color. In this case standard curve was calculated using a known
concentration of CRP and the data was expressed in mg/L.
Measurements for the NFκB activity in the plasma was conducted in three different
steps. The first step was 1) isolation of mononuclear cells from blood, 2) extraction of
nuclear and cytoplasmic extract, and 3) measuring of NFκB expression and concentration
in the nuclear extract. NFκB expression was measured using kits purchased by TransAM
NFκB (Active Motif, Carlsbad, CA, USA) as per the manufactures protocol.
Metabolomics Analysis:
Blood Samples Collection and Preparation for NMR Analysis
NMR analysis samples were randomized and obtained from the original sample
pool of subjects than selected (n=8) TRF samples and (n=7) placebo. First retrieved from
-80°C and allowed to thaw and equilibrated at room temperature. After the thawing process
was over the samples were further centrifuged at 10,000 rpm for roughly 2 minutes, in
order to remove any solid debris. Than 420μL of plasma supernatant were aliquot into pre-

23
assembled centrifugal filter and filtrate collecting tube units by Amicon Ultra with filter
parameters of 0.5mL of 3kDa unit (Sigma-Aldrich, St. Louis, MO, USA) on which cases
the filter units were washed three times prior with deionized water (450 μL deionized
water, and spun for 14,000 rpm for 5 minutes) as protocol per say. Plasma was aliquot into
each of the filtered unit tubes, than samples were centrifuged for 30 minutes at 14,000 rpm
at room temperature. The filtrates from previews step were transferred into new microtubes
at which they were prepared for dilution with deuterium oxide (D2O) to equilibrate them
into a 1:1 ratio (300μL filtrate + 300μL D2O). The final NMR working solution, was
composed of (300μL filtrate + 300μL D2O), plus additionally added 5mmol/L 3(trimehylsilyl)-1 propanesulfonic acid (TMS) and 10mmol/L Imidazole to bring the final
sample solutions into a dilute made out of 9:1 ratio. These final NMR samples are then
transferred into 5mm NMR tubes (8inches long) for analysis.
Proton 1H NMR acquisition and Spectral Processing
To acquire 1H NMR spectra, a 600MHz Agilent nuclear magnetic resonance
spectrometer was used at the temperature of 27°C to read the samples. This specific custom
made design protocol, utilized to measure free induction decay (FIDs) focused in collecting
data at 32K data-points, for a total of 64 scans, with the spectrum width of 10ppm, and the
acquisition time of 4 seconds. The water signal in this study were suppressed and this was
accomplished by pre-saturation and set the flip angle reading to 90° degrees.
After gathering the NMR FIDs data, each file was processed using ACD software
version 12.0 (Advance Chemistry Development, In., Toronto, ON, Canada) by using the
stacking technique, were 64 scanned data were compiled followed by: 1) Fourier
transformation, 2) auto-phasing, and 3) auto-baseline correction protocols. The full spectra
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for each measured sample were divided into 1000 equal bins using intelligent binning
option. Than after the spectra were digitized into a table of common integral containing a
non-negative value, the data was finally exported as text files, and transferred in SIMCAP to perform multivariate data analysis.
Multivariate Data Analysis
To perform multivariate data analysis SIMCA-P 13.05 (Umetrics, Umea, Sweden)
was used. In SIMCA each row represent a case (i.e. a patient plasma) whereas each column
represents a variable (i.e. the 1000 binned spectras). The NMR data pertaining to
metabolites was statistically analyzed using three types of mathematical algorithms: 1)
principle component analysis (PCA), 2) partial least square (PLS) and 3) partial least
square discriminant analysis (PLS-DA).
PCA was utilized first because is the simplest model which analyses values and the
best way to get the overview picture of the model before exploring into further depth. The
informations in this model resides in the correlation structure of data, were mathematical
principle explores projection of lower dimensionality designed to display the systematic
variation in data matrix-X in order to show related observations and deviations similarities
in the data set, via visual display from a score or loading plots. A PCA score plot is designed
to explain a visual summary (i.e. pattern, trends, and clusters,) of the observation and
information regarding the similarities and differences in the data (i.e. control group vs.
intervention group). The visual depiction corresponding to the loading plot is used to
explain and provide information regarding the variables (part of the spectrum i.e.
metabolite which may cause a difference), that maybe be responsible for difference and
similarities observed in the score plot [39].
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The other algorithms used for this intervention were PLS and PLS-DA which are
considered to be supervised pattern recognition analysis which is described as discriminant
analysis which looks at differences between groups in the study [39]. PLS is a regression
extension of PCA in which the Y variable(s) are added to connect with the information
provided by X variable(s). Therefore in PLS analysis the conducted analysis depicts two
matrices X (e.g. chemical descriptors) and Y (e.g. biological responses) and has two
objectives which deals with the relationship between X and Y [40]. Additionally PLS-DA
tends to identify the models which separates the classes of observation based from X
variable(s) to the hypothetical Y variable(s). In all the models the X variable(s) were
previously mean-centered and Pareto-scaled as the basis for block-scaling before
performing multivariate data analysis [41].
Metabolites Identification and Quantification
The metabolites were identified and quantified using Chenomx NMR 7.1
(Edmonton, Alberta, Canada), in which FIDs files were first processed to adjust for pH,
assign chemical shift indicator, than remove line shape distortion by auto-phasing, and
lastly auto-spline the baseline correction then reference de-convolution. The spectra in text
form were exported into Chenomx profiler for identification and quantification of the
metabolites for which there are 313 known metabolites in this database specific for a 600
MHz NMR. Each corresponding peak pertaining to a metabolite, were matched to the
existing database and the area under the peaks were used as standard which indicated the
literature concentration and manually each metabolite was adjusted to matching the
database spectra.
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Statistical Analysis
Data results from experiments were keyed into Microsoft Excel and organized
accordantly, thereafter these data were transferred into SPSS to further conduct detailed
analysis. Statistical analysis was carried out using SPSS (version 22 IBM,) and results were
presented in forms of mean ± SEM (mean ± standard error mean) on the tables and the
figures. Data that were not normally distributed were presented as median ± IQR (median
± Interquartile ranges). Categorical data were presented as absolute numbers and
percentages. Independent t-test analysis was utilized when necessary to compare values
which applied to normally distributed data, to check for differences in means between two
groups. Paired t-test analysis was used to check for differences between time points, and
chi-square test was used to test the differences in categorical data.
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CHAPTER 3
RESULTS
Characteristics of study population
Figure 3-1 describes TRF study selection and grouping of patients, which were
allocation for the duration of this clinical intervention as well as the inclusion and exclusion
factor values. A total of 81 ESRD patients were randomized into two different groups
placebo (n=37) and TRF (n=40). Both groups were provided with placebo or TRF specially
designed capsules for 16 weeks. ESRD patients were further divided into four subgroups
for further in-depth analysis of the lipid profiles and biomarkers.
Table 3-1 shows the clinical and demographic characteristics of the study
population. No significant differences were observed in all demographics and or clinical
variable measurements when comparing the data from baseline to week 16. The population
was homogenously comprised of African American patients with a semi-equal distribution
in genders of 43 males and 38 females out of 81 overall participants.
Table 3-2. Depicts the effect of TRF supplementation on plasma lipids in subset of
subjects that were taking statin drugs and those who were not. All groups were crossed
analyzed against each other in order to explore any differences in the lipid profile levels
(TAG, TC, LDL-C and HDL-C) in which case values are presented as mean ± SEM. After
various examinations, significant values between groups were reported by using
superscripts, in which case different superscripts indicate significant differences (p<0.05)
between groups within a row. The four groups were compared against each other at
allocated times, baseline, week 8, week 12 and week 16. Analysis was conducted using
independent t-test. Results showed decreases in TAG levels in plasma over time for TRF
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Non-Statin and TRF Statin groups. Significant decreases were also observed in weeks 8
and 16 among Placebo Non-Statin and (TRF Non-Statin/Placebo Statin) groups when
compared. On the other had Placebo Non-Statin and Placebo Statin did not record any
decreases of significance in TAG levels. During TC analysis, TRF Non-Statin group saw
a decrease in levels from baseline to 16 weeks, whereas TRF Statin observed a decrease
upon week 12 and not beyond. A comparison between the two groups did record a
significant decrease in TC levels at week 16 in which case favored TRF Non-Statin over
TRF Statin. There was a marginal decreasing trends of TC level among Placebo NonStatin/Statin groups up until week 12. LDL-C also observed a decrease in its levels over
time when looking at TRF Non-Statin and TRF Statin groups. Furth more at weeks 12 and
16 analysis showed significant decrease among the two groups. Placebo Statin showed a
marginal change in LDL-C, whereas Non-Statin displayed inconclusive results. HDL-C
analysis, displayed a significant increases in both groups TRF Statin/Non-Statin over time.
Incremental increase was recorded in Placebo Statin/Non-Statin groups which were of no
significance. A comparison between groups showed significance difference between
Placebo Non-Statin and TRF Non-Statin, at which point placebo had lower HDL-C levels
at baseline, but after this point levels of HDL-C increase in both groups as time went on;
in the end favoring the TRF Non-Statin group with higher HDL-C levels.
Table 3-3. It represents eleven metabolites which were discovered to have changed
significantly (p<0.05) on ESRD plasma samples in TRF group when compared to the
placebo group. The metabolites were quantified and identified using Chenomx, whereas
statistical analysis was conducted using SPSS., in which case values are represented as
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mean ± SEM. Eight out of eleven metabolites showed a significant decrease due to the TRF
intervention and three out eleven metabolites showed a significant increase.
Figure 3-2. Explores changes in CETP levels per hour between TRF and placebo
groups. Values are presented as mean ± SEM, and the units of measurement are pmol/µl.
Changes of CETP activity in the plasma were analyzed and compared among the four subgroups, using independent t-test at baseline, week 12 and week 16. At week 16 a significant
decrease (p<0.0001) in CETP was observed in TRF Non-Statin and TRF Statin groups
when compared against Placebo Non-Statin. Likewise Placebo Statin group showed a
marginal decrease in CETP level when compared to Placebo Non-Statin.
Figure 3-3. It depicts the differences in CRP levels between the TRF groups and
placebo groups. Values are presented as mean ± SEM and the measured units used were
mg/L at baseline, week 12, week 16, and week 8 was not measured. Lower CRP levels
were observed at baseline for statin TRF and non-statin placebo when compared in parallel
to changes in activity for Placebo Statin and TRF Non-Statin groups. Than on week 12
CRP levels increase significantly for TRF Statin, and Placebo Non-statin. At week 16 no
significant changes in CRP levels were observed between the groups. Different
superscripts are indicates of significance (p<0.05) change in the CRP activity levels.
Figure 3-4. Depicts NFKB activity between TRF and placebo groups. Values are
presented as mean ± SEM and the measured units used was pg/mL at baseline, and week
12, no measurements were conducted at week 8 or 16. A decreased was observed at
baseline between TRF Non-Statin and TRF Statin, and these changes were reported with
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different superscripts indicating significance (p<0.05). Week 12 showed no change in
NFκB activity between the groups.
Figure 3-5. Is the depiction of the changes in TAG levels over time among statin
and non-statin groups. Values are presented as mean ± SEM based on independent t-test
analysis. A decrease of TAG levels was recorded within groups TRF Statin and TRF S
Non-Statin at week 12 (p<0.05), but only a marginal decrease trend was observed at week
8 and 16 for the following groups. No significant difference were observed for Placebo
Statin and Placebo Non-Statin groups at either weeks 8,12, or 16 even though there are
marginal decrease in TAG levels within the study population.
Figure 3-6. It is the change in time of HDL-C levels among TRF and placebo
groups. Values are presented as mean ± SEM, were different letters indicate significant
changes over time per group (p<0.05). All groups during week 8 saw no changes in HDLC levels but a gradual increases in this lipoprotein was observed at week 12 and 16 on all
the groups. Significant differences were seen between TRF Statin and TRF Non-Statin at
both times week 12 and 16 when compared to baseline results.
Figure 3-7. Shows a PCA score plot for the NMR spectra using plasma samples on
ESRD patients at baseline, in order to observe grouping behavior. The figure overviews
the metabolomic profiles of patients who were grouped under placebo and TRF groups and
observes similarities or dissimilarities on metabolite profiles found in plasma. This PCA
showed no correlation between the two groups. The inside of the eclipse represents 95th
percentile of confidence interval and the outside of the eclipse is considered an outlier.
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Figure 3-8. Depicts the PCA score plot for NMR spectra using plasma samples on
ESRD patients measured at week 12. This PCA model shows a moderate separation
between the two groups, based on the cluster formation in relation to the eclipse graph. The
inside of the eclipse represents 95th percentile of confidence interval and the outside of the
eclipse is considered an outlier and this model shows one TRF outlier in the PCA model.
Figure 3-9. PLS-DA score plot from NMR spectra using plasma samples from
ESRD patients measured at week 12. This model show a strong correlation and clear
separation between the groups, than previews PCA score plot. The separation of two groups
and the cluster formation are observed by samples being located on different planar sides
of the eclipse.
Figure 3-10. The PLS score plot shows the correlation of metabolomic profiles and
plasma lipids profiles of TC, TAG, and HDL-C measured at week 12. It depicts the
correlation between metabolomic profiles on the (x-axis) and plasma lipid profiles (TC,
TAG, and HDL-C) on (y-axis) between the two groups. The model shows a moderate
correlation (R2 = 0.597) between the metabolomic profiles when compared the lipid
profiles, and a clear separation between the two groups when looking at the samples (TRF
and Placebo) location on the graph’s plains of symmetry.
Figure 3-11. PLS score plot correlates plasma metabolite profiles to CRP and IL6 levels. It shows a correlation between metabolomic profiles on the (x-axis) and
inflammatory markers on (y-axis) between the two groups at week 12. The model shows a
small moderate correlation (R2 = 0.38) between the two groups and the variables. A clear
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separation between the two groups is observed and clusters are formed from the two groups
which are located at opposite planes of graph regions.
Figure 3-12. PLS score plot, correlation of metabolomic profiles in the plasma and
serum albumin at week 12. It depicts the correlation between the plasma metabolomic
profiles on the (x-axis) and the serum albumin (marker of nutritional status in ESRD
patients) (y-axis) at week 12. The results indicate a strong correlation between the two
groups with a (R2 = 0.645) values which is significant.
Figure 3-13. Is a PLS model correlating antioxidant activity (TAP and MDA) - (yaxis) compared to metabolomic profiles in the plasma located on the (x-axis) at week 12.
The results indicate a small moderate correlation between the two groups which is
represented by (R2 = 0.41) values.
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Table 3-1. The table depicts baseline clinical and demographic characters of the study
population.

BMI=Body Mass Index; B/P=Blood Pressure; Kt/v=Index of Dialysis adequacy
The data is reported as mean ±SD. P-value (< 0.05) served as a comparison between
placebo and TRF groups and no significant difference was observed [35].
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Table 3-2. Effects of Tocotrienol supplementation on plasma lipids in patients also
prescribed statin drugs.

Lipid Profiles
TAG Baseline
(mg/dL)

TC
(mg/dL)

LDL-C
(mg/dL)

Week 8
Week 12
Week 16
Baseline
Week 8
Week 12
Week 16
Baseline
Week 8
Week 12
Week 16

HDL-C Baseline
(mg/dL) Week 8
Week 12
Week 16

TRF
Non-Statin
(n=23)
121±17
129±17 a
101±8
b
80±7
184±8
159±5
145±7
140±8 b
115±8
80±6
67±7 a
65±8 b

TRF
Statin
(n=17)
157±43
135±23 ab
119±13
ab
98±11
187±14
159±11
145±12
154±13 a
113±15
81±10
54±11 b
74±13 a

Placebo
Non-Statin
(n=26)
116±13
98±9 b
103±12
a
104±11
173±8
150±7
140±6
150±8 ab
108±7
81±6
73±6 ab
77±7 ab

Placebo
Statin
(n=11)
154±24
154±24 a
112±17
ab
126±16
186±15
154±11
126±14
141±13 ab
110±14
71±10
47±12 ab
60±12 ab

45±3 a
53±4
59±3
59±2.8

42±4 ab
52±4
68±5
60±6

42±2 b
49±2
51±2
52±2

45±3 ab
52±5
63±4
56±6

TC- Total cholesterol; HDL-C - High-density lipoprotein cholesterol; LDL-C - Lowdensity lipoprotein cholesterol; TAG - triglycerides
Values are presented as mean ± SEM. Different superscripts indicate significant difference
(p<0.05) between groups within a row. The four groups were compared against each other
at allocated times, baseline, week 8, week 12 and week 16. Analysis was conducted using
independent t-test.
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Table 3-3. Metabolites of change on ESRD patients using Chenomx identification
analysis when comparing TRF and placebo groups.

Note: Each sample number correlates to a peak (ppm) destination which has changed when
analyzing NMR spectrums under Chenomx analysis. P-values are represented as mean ±
SEM, and they indicates significant difference (p<0.05).

36
Figure 3-1. Depicts TRF study selection of patients’ flow chart.
Screened for Eligibility
(n=118)

Excluded (n=37)
(n=30) Due Inclusion Criteria
(n=7) Decline Participation

Randomization
(n=81)

Allocated to TRF

Allocated to Placebo

(n=41)

(n=40)
Excluded (n=1 died)

Excluded (catheter
dysfunction (n=1)

Week 1

Week 3

Excluded (n=1 transplantation)

Excluded (n=1 died)

Week 12

Analyzed TRF

Analyzed Placebo

(n=40)

(n=37)

(Including drop out)

(Including drop out)

Analyzed (n=23)

Analyzed (n=17)

Analyzed (n=26)

Analyzed (n=11)

TRF (Non-Statin)

TRF (Statin)

Placebo (Non-Statin)

Placebo (Statin)

From (n=118) to (n=81) which were selected to be used for the clinical intervention.
Patients were divided into two groups TRF (n=40) and Placebo (n=37). Subjects were
further divided into four subgroups [TRF (Non-Statin) & TRF (Statin)] and [Placebo (NonStatin) & Placebo (Statin)], in order to compare lipid changes.
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Figure 3-2. Comparison of CETP levels over time in TRF and Placebo groups.
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Values are presented as mean ± SEM. Different superscripts indicate significant difference
in CETP levels (p<0.0001). Non-Statin TRF and Statin TRF observed significant decreases
when compared to Non-Statin Placebo. Whereas Statin Placebo showed a marginal
decrease in conjunction to Non-Statin Placebo. Analysis was conducted using independent
t-test, at allocated times, baseline, week 12 and week 16 and only difference was observed
on week 16.
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Figure 3-3. CRP comparison between TRF groups and Placebo groups
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Values are presented as mean ± SEM. Different superscripts indicate significant difference
(p<0.05) between groups.
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Figure 3-4. NFκB activity between TRF and Placebo groups.
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Values are presented as mean ± SEM. Different superscripts indicate significant difference
(p<0.05) between groups. Statin placebo was compared to non-statin placebo, for the NFκB
activity in the plasma, at allocated times, baseline and week 12. Analysis was conducted
using independent t-test. Significance was observed at baseline a) p=0.052 and b) p=0.051
and at week 12 no significance was observed.
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Figure 3-5. Change in TAG Levels among Statin and Non-Statin Groups
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Values are presented as mean ± SEM. The graph depicts the decreasing TAG levels over
the course of time, on all four groups. TAG data was calculated by different from baseline
values. Symbol * indicates significant difference (p<0.05), based on independent t-test
analysis.
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Figure 3-6. Change in time of HDL-C levels among Statin and Non-Statin Groups
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Values are presented as mean ± SEM. The graph depicts the increasing HDL-C levels over
the course of time, on all four groups. HDL-C data was calculated by different from
baseline values. Different letters indicate significant changes over time per group (p<0.05),
based on independent t-test analysis.
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Figure 3-7. PCA score plot from NMR spectra using plasma samples from ESRD
patients at baseline

PCA- principal component analysis; Pla-placebo; Trf- tocotrienol-rich fraction.
The figure is a depiction of PCA-X score plot at baseline, indicating the metabolomic
profiles of ESRD patients under the placebo and TRF treatments. The inside of the eclipse
represents 95th percentile of confidence interval and the outside of the eclipse is considered
an outlier.

43
Figure 3-8. PCA score plot from NMR spectra using plasma samples from ESRD
patients at Week 12.

PCA- principal component analysis; Pla-placebo; Trf- tocotrienol-rich fraction.
The figure is a depiction of PCA-X score plot at week 12, showing the metabolomic
profiles of the same ESRD patients on the placebo and TRF treatment groups which were
previously analyzed from baseline. The inside of the eclipse represents 95th percentile of
confidence interval and the outside of the eclipse is considered an outlier. The circled in
red TRF sample represents an outlier in the PCA.
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Figure 3-9. PLS-DA score plot from NMR spectra using plasma samples from ESRD
patients at Week 12.

PLS-DA partial least square-discriminant analysis; Pla-placebo; Trf- tocotrienol-rich
fraction.
The figure is a depiction of PCA-X score plot at week 12, showing the metabolomic
profiles of ESRD patients on the placebo and TRF treatment groups. The graph shows a
clear separation between the two groups and their metabolites in the plasma.

45

Plasma lipid profiles

Figure 3-10. PLS score plot correlating metabolomic profiles and plasma lipids profiles
(TC, TAG, and HDL-C) at week 12.

NMR plasma metabolomic profiles
PLS- partial least square; Pla -placebo; TRF- tocotrienol-rich fraction;
TC - total
cholesterol; TAG -triacylglycerol; HDL-C - high-density lipoprotein cholesterol.
The figure shows PLS score plot, depicting correlation between metabolomic profiles on
the (x-axis) and plasma lipid profiles (TC, TAG, and HDL-C) on (y-axis) between the two
groups at week 12. The model shows a moderate correlation (R2 = 0.60) between the
metabolomic profiles and the lipid profiles.

46

CRP & IL-6 Levels

Figure 3-11. PLS score plot correlating plasma metabolite profiles to CRP and IL-6
levels.

NMR plasma metabolomic profiles
PLS- partial least square; Pla -placebo; TRF- tocotrienol-rich fraction;
Reactive Protein; IL-6 – Interleukin 6

CRP- C -

The figure shows PLS score plot, depicting correlation between metabolomic profiles on
the (x-axis) and CRP/IL-6 on (y-axis) between the two groups at week 12. The model
shows a moderate correlation (R2 = 0.38) between the plasma metabolomic profiles and
two the pro-inflammatory markers.
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Serum Albumin Levels

Figure 3-12. PLS score plot, correlation of metabolomic profiles in the plasma and serum
albumin at week 12.

NMR plasma metabolomic profiles

PLS- partial least square; Pla -placebo; TRF- tocotrienol-rich fraction
The figure show PLS score plot depicting the correlation between the plasma metabolomic
profiles on the (x-axis) and the serum albumin (marker of nutritional status in ESRD
patients) (y-axis) at week 12. The results indicate a correlation between the two groups
with a (R2 = 0.65) values.
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TAP & MDA Levels

Figure 3-13. PLS correlation of TAP and MDA compared to metabolomic profiles in the
plasma.

NMR plasma metabolomic profiles
PLS- partial least square; Pla -placebo; TRF- tocotrienol-rich fraction;
TAP - Total Antioxidant Power; MDA- Malondialdehyde

The figure show PLS score plot depicting the correlation between the plasma metabolomic
profiles on the (x-axis) and the antioxidant (MDA and TAP) activity (y-axis) at week 12.
The results indicate a small moderate correlation between the groups with a (R2 = 0.41)
values.
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CHAPTER 4
DISCUSSION
CKD patients with ESRD experience an accelerated form of atherosclerosis due to
increase in inflammation, increase in oxidative stress and the decrease in cellular
antioxidant levels. Therefore by supplementing with 220 mg/day of vitamin E –
tocotrienol-rich fraction for 16 weeks, it was hypothesized that this supplement may help
reverse and improve oxidative stress, inflammatory markers and increasing the antioxidant
activity, in conjunction with improving lipid profiles of HD patients.
The demographic characteristics of the study depict a homogeneous, African
American ethnic population in order to reduce variation. Parameters in both groups
(placebo and TRF) age, ethnicity, gender, smoking and the clinical parameters distribution
were analyzed and demonstrated no significant differences Table 3-1, thus any potential
comorbidities, and conforming assumption factors influencing the outcome, were
minimized. In this study lipid profiles (TAG, TC, LDL-C and HDL-C) were measured for
both groups (placebo and TRF) at baseline, week 8, 12 and 16, on which case they were
further analyzed for the duration of this intervention for changes in blood plasma. Because
ESRD patients are at a high risk for various CVD induce illness, some patients were under
the use of statins medications which were approved by their health provider. Additionally
the sub-groups of statin users were allowed in this intervention in order to explore any
synergistic effects between TRF and statin and whether they affect our measured
parameters. Therefore in this study patients were further sub-divided into four additional
groups (TRF Non-Statin, TRF Statin, Placebo Non-Statin, and Placebo Statin) Figure 3-1,
at which point results were analyzed for changes in lipid profiles when groups were
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compare against each other Table 3-2. The study also analyzed the CETP activity levels in
the plasma Figure 3-2 in order to correlate any changes observed to the lipid profiles. As
previously mentioned, this is the first study of its kind, which uses vitamin E-tocotrienols
as an intervention supplement on ESRD patients, due to the fact that TRF as a micronutrient
contains antioxidant properties that could help fight oxidation, free radicals and obtains
lipid lower properties. Also measurements were conducted on NFκB, a protein which is
involved in cellular responses, and measurement were taken for CRP as well as IL-6 proinflammatory markers. Analysis of lipid profiles was processed using SPSS, and the results
were extended to metabolomic analysis, which was conducted using 600 MHz NMR.
Furthermore metabolites in the plasma were compared and analyzed using SIMCA-P
models, than Chenomx was utilized for quantification/identification of metabolites which
changed.
Lipoprotein Profile Effects
One of the most important changes that the study discovered was the decrease in
TAG levels from baseline to week 16. An overall gradual decrease in TAG levels was
observed over time between TRF Non-Statin (n=23) and TRF Statin (n=17) groups Table
3-2. No decreasing trends or patterns were observed over time when looking at the Placebo
Non-Statin group, but the Placebo Statin saw sporadic decreases in TAG levels at weeks
8-12 and an increase at week 16. TAG results were also compared in parallel for changes
between the sub-groups. It was discovered that during week 8 when comparing TRF NonStatin to Placebo Non-Statin a significant change in TAG levels was recorded which
favored a higher decrease of Placebo Non-Statin. This type of analysis was carried out
between the same groups at week 16, and again a significant change was observed but this
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time it favored TRF Non-Statin group which recorded a much lower TAG decrease. It is
postulated that the reason TAG levels were reduced more on the later weeks during the
study might have to do with the fact that TRF supplementation, needs time to build up in
order to effect the metabolism pathways of triacylglycerol’s. A good visual changes over
time in TAG levels between the four sub-groups is observed on Figure 3-5. This time
course graph show a significant decrease of both TRF Statin and TRF Non-Statin at week
12, at which point this marginal decrease was carried over at week 16. As shown in the
graph Placebo Statin observes a clear decreases in TAG levels at weeks 12-16 proving that
these medications are also effecting the patients. Therefore is worth postulating that statin
drugs are effecting in aiding to change TAG level, as shown by TRF Statin and Placebo
Statin results. Statin drugs are known to induce inhibition of HMG-CoA reductase which
leads to a decrease of hepatic cholesterol pools and subsequently decreases in production
Apo-B contacting VLDL particles and the fact that LDL receptors are up-regulated. VLDL
plays a key role in TAG trafficking of lipoprotein in fasting plasma, therefore statins drugs
reduce TAG by enhancing clearance of VLDL, and reuptake of LDL occurs via LDL
receptors, therefore this would be the path speculated which is imposing a decrease of the
TAG and LDL. Another interaction worth speculating as possible affect in the decrease of
TAG levels is the synergistic link between statin drugs and TRF supplements which
possibly act in inducing inhibition of HMG-CoA reductase Table 1-3.
Total cholesterol (TC) levels were also affected, were an overall significant
decrease over time is observed in TRF Non-Statin group from start to end, and likewise
TRF Statin observed a more gradual decrease until week 12. Additionally Placebo Stain
group observed marginal decreases from baseline to week 16, and Placebo Non-Statin
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group did not see any significant decreasing patterns Table 3-2. Comparison analysis
between TRF Non-Statin and TRF Statin (week 16) discovered a significant decrease in
TC levels, which favored a bigger decrease in TRF Non-Statin group. This is an important
results because it strengthens the notion that TRF supplementation offers lipid altering
effects, as recorded in these results, correlating to preview literature with
hypocholestrolemic issues were TT exhibits unique lower effect. This could be due to TRF
effecting post-transcriptional suppression of HMG-CoA reductase protein, and the
enhancement of ubiquitination of HMG-CoA reductase Table 1-3.
LDL-C was another altered lipid which observed a decreasing trend, and in this
case it was an overall change from baseline to week 16 observed only in TRF Non-Statin
group. On the other side TRF Statin group showed a similar gradual decreased in LDL-C
level but failed to progress into week 16. Comparison analysis between these two groups
showed a significant change in LDL-C favoring a higher decrease in TRF Statin group
levels up to week 12, than on week 16 levels increased marginally, whereas Non-Statin
TRF showed a significant decrease compared to its counterpart (week 16) Table 3-2. Statin
Placebo/Non-Statin groups showed small decreases in LDL-C levels which were not
significant but both groups like TRF Statin observed in increase at week 16 when
comparing levels to week 12.
Last lipid results which the study effected were the HDL-C levels in which case in
TRF Non-Statin group observed an increase in levels from baseline to week 16, similar
trend was observed in TRF Statin group but only up to week 12. On the other side the
Placebo groups whether Statin or Non-Statin did not show any significant increases in
HDL-C level, but they were followed by marginal increases throughout the study Table 3-
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2. A time course comparison between TRF Non-Statin and Placebo Non-Statin showed a
significant increase of higher HDL-C levels favoring the TRF group. Figure 3-6 a change
in time of HDL-C levels among the groups depicts the important of supplementing with
TRF in ESRD patients who are under Statin medication and or Non-Statin, result show a
significant increase (p<0.05) in this lipoprotein from baseline to weeks 12 and 16. The
increase in HDL-C levels in the plasma, it is postulate could be due to the increased
production of HDL particles, the delayed catabolism of HDL particles or the higher
cholesterol contents in HDL particles. Another mechanism forcing these results would be
the effect of tocotrienols (TT) on the TAG and HDL-C levels at week 12 and 16. Levels
for ApoA1 and CETP were also measured in this study although ApoA1 were not discussed
in this thesis the levels were significantly higher in the overall TRF groups during week 12
(p<0.05), which also coincided with the higher levels of HDLC-C in TRF group’s overall
[35]. The reason why ApoA1 is important, is because it is a major protein in HDL particle
(estimated is 70% of HDL particle), in which aids in clearing fats including cholesterol.
Therefore increase in HDL-C levels at week-12 in the TRF groups is explained by the
increase in HDL particles which mirrors the increase in ApoA1 at week 12 and this
correlation was further solidified by the Pearson’s test during weeks 12 and 16 [35]. It is
speculate that a link seems to exist in this study were TRF supplementation has
significantly affected an increase in HDL-C which was reflected by higher levels of ApoA1
concentration in the plasma. Literature on TT effecting ApoA1 is scarce but a the study by
Heng et al [42] does demonstrate the increased expression of ApoA1 precursor when this
form of vitamin E (TT) is supplemented.
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It worth extrapolating that TRF and TP supplementation, in which case exhibit
antioxidant like mechanisms could possibly effect several transcriptional factors such as
MAP, PPARα and PPARγ in the up-regulation of proapoA1 [43]. The other marker that
was seen to have a lower activity in the overall samples was CETP in TRF group during
week 16, in which case it parallels higher HDL-C levels. Significant decreases in CETP
levels resulted between Placebo Non-Statin and TRF Non-Statin groups, in which case at
week 16 the TRF groups had bigger decreases than its counterpart (placebo) by P<0.0001
Figure 3-2. A decrease in CETP levels was also seen between Placebo Statin and Placebo
Non-Statin comparison, in which case the statin group had a higher decrease than its
counterpart even though the sample number are not equivalent in patient number
(p<0.0001) Figure 3-2. CETP plays an important role in lipid metabolism because it
mediates the transfer of cholesterol ester from HDL to VLDL remnants in exchange for
triacylglycerol’s [44]. In this hemodialysis population, patients are experiencing delayed
catabolism of TAG rich lipoprotein, so it is speculated that CETP activity may increase in
facilitating that TAG-cholesterol transfer between HDL and apoB100 lipoprotein. A recent
study made the correlation in HD patients in having higher levels of CETP when compared
to control [45] which ultimately is depicted by lower HDL-C levels and higher TAG levels
in this population. In our study CETP had significantly decrease and further analysis using
Pearson’s correlation test between CETP and TAG (a decreased) concentration, at weeks
12 and 16 confirms significant correlation between the two variable. Therefore the second
metabolic pathway to consider which improved lipids in decreasing TAG and increasing
HDL-C could be CETP mechanisms due to the decrease of its activity levels.
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Figure 3-3 explore the changes in the CRP activity between TRF and Placebo
groups. It was discovered that CRP levels were significantly lower at baseline compared
to weeks 12 and 16. Even though CRP levels increase after baseline it is worth noting that
TRF Statin group overall had lower average CRP levels throughout the study. ESRD
population has been linked to higher levels of inflammation in the body than normal people,
in which case leads to major health issues like CVD’s, therefore preferred outcome would
be to lower CRP in order to lower inflammation but this study was not able to reduce the
CRP levels significantly by supplementing with TRF and or statin use did not affect levels
by much. The reason for not achieving this goal could be due to multiple acumen, possible
due to higher inter-individual variability in CRP levels, which often is associated with
transient inter-current clinical evens and the dynamic response of the human immune
system or even the simple fact that CRP fluctuates dramatically upon acute inflammation
[46]. In a similar fashion NFκB activity was measured at baseline and week 12. It was
observed that the activity of NFκB was significantly lower at baseline when TRF Statin
was compared to TRF Non-Statin, but no significances were observed on the other two
groups at ether time lines. The same measurement was conducted at week 12 looking for
changes between the groups, but no such data was recorded Figure 3-4. NFκB which is
found in almost all the human cells plays a key role in cellular responses to stimuli of stress,
pro-inflammatory agent such as cytokines and CRP. Due to the fact ESRD patients are
prone to increased levels of inflammation in their bodies it was postulated that TRF would
reverse these effects. The only marginal effect that could be correlated, was the fact that
TRF supplementation in conjunction with prescribed Statin drugs seem to marginally help
lower NFκB, but only at baseline.
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Metabolomic Analysis
Analysis of the plasma metabolomic profiles in HD patients was conducted using
SIMCA-P in order to compare and find difference between TRF and placebo group. Unlike
previews tests in this part of the study no statin users were included in these analysis. The
first analysis conducted was unsupervised PCA-X graph at baseline which found the
metabolites being spread throughout the graph which means no correlation between the
two groups Figure 3-7. Than after PCA was conducted just for week 12 Figure 3-8 and
there was some separation between the two groups unlike in the baseline results. To
validate the separation between the two groups PLS-DA model was utilize from the NMR
spectra using plasma samples on ESRD patients at Week 12, a discriminate form analysis
on which case observe a clear separation between the two groups, which meant a significant
difference between TRF and placebo metabolome profile Figure 3-9. After establishing a
difference between TRF and placebo groups, analysis was conducted using PLS score plot
between metabolomic profiles and plasma lipid profiles (TAG, TC, and HDL-C). The
results showed a very high correlation as well as separation between the two group
exemplified by the significant R2=0.597 value Figure 3-10. These results establish a
significant difference in NMR metabolomic profiled of ESRD patients, and their plasma
lipid profiles making a fair conclusion that TRF groups have different lipid composition
than the placebo groups. The difference in lipid profile in TRF group when compared to
placebo is exemplified by the increase of HDL-C, and the decreases observed in TAG and
TC levels. We can summarize that there is strong correlation that by supplementing with
tocotrienol-rich fractions for 12 weeks the study observed a positive link, in altering the
lipid profiles in ESRD population to patients’ plasma metabolites.
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Additionally PLS plot was also used to analyze the plasma metabolite profiles to
CRP and IL-6 level activity in this population. As it was reported previously in the plasma
analysis IL-6 and CRP showed no significant changes in effecting any pro-inflammatory
markers. In this PLS model we observed moderate difference between the TRF and placebo
groups by utilizing two component variable analysis (CRP/IL-6 vs. plasma metabolomic
profiles) in which case we observe a small marginal correlation based on R2=0.38 value.
Because of these results on how the TRF and placebo group are observed and clustered
Figure 3-11, it could be speculated that TRF groups have affected on some degree the
inflammatory markers, based on their antioxidant properties and the fact that the TRF
group is located at the opposite quadrant on the graph when comparing it to placebo. This
maybe none-significant but it would be something worth exploring in future studies with
bigger populations as well as statin plus TRF users since this analysis does not factor any
statin users. An important analysis by PLS score plot which was discovered, was the
correlation of metabolomic profiles in the plasma and serum albumin levels, in which case
observed a significant difference and separation between TRF group and Placebo and this
is validated by R2=0.645 Figure 3-12. This basically could attribute to TRF protective
properties in reducing protein or amino acid degradation, and could be considered a
positive link in reduction of inflammation. Last PLS model which was analyzed was the
correlation of TAP and MDA in comparison to metabolomic profiles in the plasma Figure
3-13. In this case there seems to be a very small correlation non-significant, R2= 0.41
between two variables and the inner antioxidant molecules which are found in the plasma.
Unfortunately there is not a strong link to conclude anything from these finding, this maybe
an area for future clinical trial to explored and expand on. Moreover metabolomics profile
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analysis in both TRF and placebo does conceives a correlation between inflammatory
markers and lipid profiles, suggesting that some plasma metabolites cold predict changes
in lipid and inflammatory biomarkers. The comparison and exploration conducted in this
thesis was to identify any metabolites of change on ESRD patients using Chenomx
(quantification and identification) analysis when comparing TRF and placebo groups NMR
spectrums. After our analysis identified roughly 311 metabolites for which patients in both
groups TRF and placebo shared. Scrutinizing the data in further detail, when comparing
TRF and placebo groups it was discovered that eleven metabolites were categorized to have
incurred a significant change in the metabolome profile (p<0.05) Table 3-3. In this event
8 out 11 metabolites saw a decrease in their expression, and 3 out 11 saw an increase in
their expression. Preliminary results of metabolites which changed, after being identified
via Chenomx, does reveals that TRF supplementation triggers changes in ESRD, which
leading to ether reduction/increase in several biomarkers. The names were identified, as
well as the role they play in human metabolism, but currently this data is under further
validations before being released to the public.
Conclusion
In the beginning of this study it was hypothesized that by supplementing with
tocotrienol rich fraction (TRF) a vitamin E, for 16 weeks in ESRD patients undergoing
hemodialysis, it may help to reverse and/or improve; oxidative status, inflammatory
markers, increase antioxidants status and improve lipid profiles in this population.
Regrettably this postulated hypothesis did not completely come to fluidity. The only
portion of the hypothesis which came true was the fact that HD population who have incur
ESRD seemed to observe a change and improvement on lipid profiles when using this
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micronutrient, as well as when combining it with statin medications. This study also
observed a minor link on synergism when combining Statin drugs with TRF, but this
remark requires further analysis and validation. Experimentation conducted in regards to
reducing oxidative status, inflammatory markers and increase in antioxidant activity,
showed the results to be inconclusive, therefore disproving the other portion of this
postulated hypothesis.
This clinical intervention using ESRD patients provided conclusive results for
future studies in which case, when statin drugs are combined with TRF-vitamin E
supplements, and/or TRF Non-Statin alone is given to patients, this seems to improve HD
subjects’ lipid profiles. A significant decrease of TAG levels was observed as well as an
increase in HDL-C was recorded in this clinical study. These results were reflected by the
increase in ApoA1 and the decrease in CETP levels Whereas TC and LDL-C observed
incremental decreases which need further validation. Using metabolomic analysis further
evidence provided that TRF supplementation seemed to have a positive effect in improving
and changing lipid profile (TC, TAG, and HDL-C) when compared to placebo. Therefore
in this study it was established that TRF supplementation does trigger a change in ESRD
metabolome profile.
Even though this study fell short to provide a significant effect from TRF
supplementation into improve oxidative, inflammatory and antioxidant status in ESRD
patients, various PLS-models using SIMCA-P showed moderate changes and correlations
when looking at NMR metabolomic profiles compared to the variables tested (oxidative,
inflammatory, antioxidant) in TRF and placebo groups. Correlation between lipid profiles
and plasma metabolome shows a significant difference between TRF and placebo groups.
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The metabolomic profile analysis in TRF and placebo does display a correlation when
looking at inflammatory biomarkers to lipid profiles suggesting that the plasma metabolites
could be used to predict changes in biomarkers. Based on the PLS models that we provided,
future studies with bigger pool size of subjects maybe need in order to overturn these
inconclusive findings.
Future Directions
Future study should focus in validating the eleven metabolites which were found to
have significant changes in the TRF metabolome. After identifying them (by name) the
focus should turn to the role they play in the human metabolism (metabolic pathways) and
how do these metabolites effect ESRD patients in the long run. It is important to see if there
are any links between these biomarkers and how they influence inflammation, oxidative
status and antioxidant activity levels. Also future studies should definitely focus in
establishing a bigger pool size of subjects for these type of clinical interventions, so
researchers can reduce errors due to patients’ compliance availability, when analyzing the
results. Lastly, future studies should focus in establishing whether there is a synergistic link
between Statin with TRF supplement when using NMR (metabolomic) as a method of
testing.
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Chronic kidney disease (CKD) is known as a heterogeneous disorder which
currently is on the rise and lately has been classified as a public health issues in the United
State and worldwide. CKD is an irreversible and progressive disease which can lead to
kidney failure, and this is depicted by the advanced stage of the disorder when it reaches
the point, that is classified as end stage of renal disease (ESRD) (Stage 5 of CKD) (eGRF
<15 mL/min/ 1.73 m2 working capacity), where both organs are in a total or permanent
kidney failure. End-Stage renal disease patients, on hemodialysis have been associated to
experience an accelerated form of atherosclerosis, which is induced by inflammation,
impairment of antioxidant system and elevated oxidative stress. Since the problem
effecting ESRD patients is multifactorial, the objective of this investigation is to explore
and look at the effects of supplementing with vitamin E-tocotrienol rich fraction (TRF), a
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micronutrient which has anti-inflammatory, antioxidant, and lipid lower capabilities into
tackling these comorbid conditions experienced by this population. Therefore the aims of
this investigation will be to explore changes in lipid profiles, inflammatory markers, and
oxidative status, as well as look at any changes in metabolomic profiles. It was
hypothesized that by supplementing with TRF a vitamin E, for 16 weeks in ESRD patients
undergoing hemodialysis, it may help reverse and/or improve, oxidative status,
inflammatory markers, increase antioxidants status and improve lipid profiles.
The study was double-blinded, randomized, parallel, placebo-controlled design
trial, of 81 adult patients undergoing chronic hemodialysis at Great Lake Dialysis Clinic,
Detroit MI, where patients routinely received hemodialysis treatments 3 days a week.
These HD patients were randomly divided into two different groups before the nutritional
intervention began; a placebo group (n=40) and intervention group TRF (n=41). The
patients in the TRF group received 2 x 110 mg/day (220 mg/day) of vitamin E tocotrienol
(90 mg of TT and 20 mg of TP) whereas the placebo group patients received 2 x 0.68
mg/day of placebo (0.24 mg of TT and 0.44 mg of TP). Blood samples were collected at
baseline, week 8, week 12 and 16 in order to perform biochemical analysis of lipid profiles
(TC, TAG, LDL-C, and HDL-C), and then after analyze inflammatory markers, measured
using enzymatic kits (CRP, NFκB, IL-6). And last part of the study revolved around
metabolomics analysis on the plasma samples using (600MHz) NMR technology, than
explore changes in metabolomic profile (biomarkers) in ESRD population.
The study recorded changes and improvement on lipid profiles of ESRD patients.
A significant decrease of TAG levels was observed as well as an increase in HDL-C was
recorded. The change in TAG levels and HDL-C increase, correlated with the decrease in
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CETP levels and increase of ApoA1 in the plasma. Other lipid profile like TC and LDL-C
observed marginal decreases which were not significant, therefore further detailed analysis
is required. In this analysis patients were further divided into four sub-groups to establish
links between TRF and statin drugs. It was concluded that based on lipid profiles and
metabolomic (NMR) analysis, there seem to be some small correlations of synergism
effects when combining Statin drugs with TRF supplements but in order to validate
conclusively this minor links, further detailed analysis is required. Study did established
that TRF supplementation does trigger a change in ESRD metabolome profile. A
correlation between lipid profiles and plasma metabolome shows a significant difference
between TRF and placebo groups. Metabolomic profile analysis in TRF and placebo does
display a correlation when looking at inflammatory biomarkers to lipid profiles which
suggests that plasma metabolites could be used to predict changes in biomarkers. The study
did not find any significant changes on inflammatory and oxidative markers. Research into
biomarkers of ESRD metabolome when using (Chenomx) did discover and identify eleven
biomarkers of importance in human metabolism that observed a significant change due to
TRF supplementation when compared to its counterpart placebo group. Therefore in
conclusion this investigation has revealed that TRF supplementation does reveal to trigger
changes in ESRD metabolome that could be used for disease prediction in HD patients.
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